Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Mintun

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
CNS Spectrums|November 8, 2005
Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer's diseaseMark A Mintun
CNS Spectrums|November 5, 2008
FDG and amyloid positron emission tomographyMark A Mintun
Annual Review of Neuroscience|June 17, 2006
Brain work and brain imagingMarcus E Raichle, Mark A Mintun
Alzheimer'S Research & Therapy|April 5, 2011
PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's diseaseMichael J Pontecorvo, Mark A Mintun
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injuryDelphine L Chen, Mark A Mintun, Daniel P Schuster
The New England Journal of Medicine|August 11, 2021
Donanemab in Early Alzheimer's Disease. ReplyMark A Mintun, Alette M Wessels, John R Sims
Neuroimage|October 13, 2006
Human brain glucose metabolism may evolve during activation: findings from a modified FDG PET paradigmAndrei G Vlassenko, Melissa M Rundle, Mark A Mintun
Archives of Neurology|December 17, 2009
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta depositionMartha Storandt, Mark A Mintun, Denise Head, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|September 21, 2004
Cerebral perfusion response to successful treatment of depression with different serotoninergic agentsAndrei Vlassenko, Yvette I Sheline, Keith Fischer, et al.
Psychiatry Research|March 7, 2006
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot studyJose Mathews, Keith S Garcia, Mark A Mintun, et al.
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
CNS Spectrums|November 8, 2005
Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer's diseaseMark A Mintun
CNS Spectrums|November 5, 2008
FDG and amyloid positron emission tomographyMark A Mintun
Annual Review of Neuroscience|June 17, 2006
Brain work and brain imagingMarcus E Raichle, Mark A Mintun
Alzheimer'S Research & Therapy|April 5, 2011
PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's diseaseMichael J Pontecorvo, Mark A Mintun
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injuryDelphine L Chen, Mark A Mintun, Daniel P Schuster
The New England Journal of Medicine|August 11, 2021
Donanemab in Early Alzheimer's Disease. ReplyMark A Mintun, Alette M Wessels, John R Sims
Neuroimage|October 13, 2006
Human brain glucose metabolism may evolve during activation: findings from a modified FDG PET paradigmAndrei G Vlassenko, Melissa M Rundle, Mark A Mintun
Archives of Neurology|December 17, 2009
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta depositionMartha Storandt, Mark A Mintun, Denise Head, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|September 21, 2004
Cerebral perfusion response to successful treatment of depression with different serotoninergic agentsAndrei Vlassenko, Yvette I Sheline, Keith Fischer, et al.
Psychiatry Research|March 7, 2006
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot studyJose Mathews, Keith S Garcia, Mark A Mintun, et al.
Pageof 14